Haemato-oncology: High-Quality Care and Access to Innovations
The Ministry of Health of the Russian Federation combined efforts with federal and regional healthcare organizers to achieve significant progress in providing high-quality medical care to patients with haemato-oncological diseases. Haemato-oncology is included in the Oncological Disease Management Federal Programme, national clinical recommendations, treatment protocols and standards are updated. Additionally, a unified digital outline is created to monitor the situation and to forecast the amount of medical care for patients, plus latest generation target drugs are gradually included in restrictive lists. According to leading federal centres and regional experts, in order to significantly increase the access to high-quality medical care for patients with haemato-oncological diseases today, additional focus is needed on the following aspects: increased financing, timely experience exchange among federal and regional experts, teaching regional healthcare experts and organizers the principles resource base usage (working with the digital outline, planning the needed volume of medical care). Also, when choosing the most effective treatment in addition to achieving the best clinical results considerations should include effective expenditure of budget resources.
● What are the perspectives for further improvement of clinical recommendations for treatment of haemato-oncological diseases (using CLL and AML as examples)?
● Is it possible to adjust approaches and principles of budget planning for treatment of patients, once there are target drugs with a fixed course of treatment?
● Has the level of availability of highly effective and innovative (target) treatments been updated since haemato-oncology was included in the Oncological Disease Management Federal Programme? (using CLL as an example)?
● What is in store in terms of organizational innovations in providing high-quality medical care to patients (creating a single management and succession care outline, using CLL as an example)?
● How will increased financing of 14 high-cost ICD codes impact availability of target treatments for patients with haemato-oncological diseases?
Aleksandr Petrov, Chairman of the Subcommittee on Circulation of Medicines, Development of the Pharmaceutical and Medical Industry of the Committee of the State Duma of the Russian Federation on Health Protection
Jerome Bouyer, Area Vice President–EEMEA, AbbVie (online)
Evgeny Kamkin, Deputy Minister of Health of the Russian Federation
Andrey Kaprin, Director, Federal State Budgetary Institution National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Dmitry Morozov, Deputy, Chairman of the Health Protection Committee, State Duma of the Federal Assembly of the Russian Federation
Valery Savchenko, General Director, National Medical Research Centre for Haematology Federal State Budgetary Institution under the Ministry of Health of Russia; Senior Independent Haematology Expert for the Ministry of Health of Russia (online)
Elena Chernyakova, Chairman, Federal Compulsory Medical Insurance Fund
Front row participants
Sergey Voloshin, Head, Clinical Department of Chemotherapy of Hemoblastosis, Depression of Hematopoiesis, and Bone Marrow Transplantation, Russian Research Institute of Hematology and Transfusion Medicine, Federal Medical-Biological Agency (online)
Lilia Matveeva, President, Russian Society of Hematology "SODEJSTVIE" (online)
Irina Poddubnaya, Head of Department of Oncology and Palliative Care, Russian Medical Academy of Continuing Professional Education under the Ministry of Health of Russia (online)
Vadim Ptushkin, Senior Independent Haematology Expert, Deputy Chief Medical Officer for Haematology at Moscow City Haematology Centre of the Botkin Clinical City Hospital under Healthcare Department of Moscow, Doctor of Medicine, Professor (online)